For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.

Noninvasive hippocampal blood-brain barrier opening in Alzheimer's disease with focused ultrasound

TitleNoninvasive hippocampal blood-brain barrier opening in Alzheimer's disease with focused ultrasound
Publication TypeJournal Article
Year of Publication2020
AuthorsRezai AR, Ranjan M, D'Haese P-F, Haut MW, Carpenter J, Najib U, Mehta RI, J Chazen L, Zibly Z, Yates JR, Hodder SL, Kaplitt M
JournalProc Natl Acad Sci U S A
Date Published2020 Apr 13
ISSN1091-6490
Abstract

The blood-brain barrier (BBB) presents a significant challenge for treating brain disorders. The hippocampus is a key target for novel therapeutics, playing an important role in Alzheimer's disease (AD), epilepsy, and depression. Preclinical studies have shown that magnetic resonance (MR)-guided low-intensity focused ultrasound (FUS) can reversibly open the BBB and facilitate delivery of targeted brain therapeutics. We report initial clinical trial results evaluating the safety, feasibility, and reversibility of BBB opening with FUS treatment of the hippocampus and entorhinal cortex (EC) in patients with early AD. Six subjects tolerated a total of 17 FUS treatments with no adverse events and neither cognitive nor neurological worsening. Post-FUS contrast MRI revealed immediate and sizable hippocampal parenchymal enhancement indicating BBB opening, followed by BBB closure within 24 h. The average opening was 95% of the targeted FUS volume, which corresponds to 29% of the overall hippocampus volume. We demonstrate that FUS can safely, noninvasively, transiently, reproducibly, and focally mediate BBB opening in the hippocampus/EC in humans. This provides a unique translational opportunity to investigate therapeutic delivery in AD and other conditions.

DOI10.1073/pnas.2002571117
Alternate JournalProc. Natl. Acad. Sci. U.S.A.
PubMed ID32284421